FDA Finalizes Guidance on Antiviral Drugs for Cold Sores
By Michael Mezher -
Published 07 November 2017
The US Food and Drug Administration (FDA) on Tuesday finalized guidance on developing antiviral drugs for recurrent herpes labialis (RHL), commonly referred to as cold sores, which affects between 20% and 40% of adults in the US.
Categories: News, US, FDA, Clinical, Drugs, Preclinical
Tags: Antiviral, Recurrent Herpes Labialis, RHL, Cold Sores